Developing a clinical decision support tool for rural antibiotic stewardship
Developing a clinical decision support tool for antibiotic stewardship in rural hospitals is more than digitising prescribing guidelines. The tool must help clinicians choose, review and stop antibiotics when information is incomplete, staffing is distributed and decisions cannot wait. It should strengthen clinical reasoning, not turn a broad recommendation into an automatic order. That distinction is essential for safe, useful digital health.
Queensland’s geography shapes the challenge. A patient admitted near Charleville, Roma or Mount Isa may need treatment long before an overnight microbiology specimen reaches a laboratory, while follow-up can involve hundreds of kilometres of road and air travel. The Brisbane Diamantina Health Partners network can connect clinical data, research expertise and local implementation knowledge across rural and regional services.
Start with the rural prescribing problem
At a small rural hospital, the first antibiotic decision is often empirical: clinicians balance likely pathogens, illness severity, previous cultures, allergies and local resistance patterns. A locum covering nights or weekends may not know which pathway local teams use. Overnight specimens may go to a metropolitan laboratory, and a teleconference with an infectious diseases specialist can occur after antibiotics have already been given. Each delay creates another point where guidance can help, provided it reaches the clinician at the right moment.
Resource constraints also make workload visible. A pharmacist may support several hospitals from a regional hub, while infection prevention and microbiology advice arrives through different channels. Supporting clinicians, families and carers in remote communities requires decisions that work beyond the hospital ward. The design target should therefore be a shared decision pathway: initial therapy, early review, narrowing when results return, and a clear handover at discharge.
Turn clinical evidence into usable guidance
A useful tool supports judgement rather than replacing it. For an adult with suspected sepsis, it could combine observations, allergy status, renal function, recent microbiology and local empirical therapy guidance to propose an initial regimen and a review time. Pregnancy, children and suspected infection in an immunocompromised patient need different pathways and appropriate specialist input. Every recommendation should show its reasoning, evidence source and last-review date, so busy clinicians can interpret it quickly.
Rules need co-design with rural prescribers, pharmacists, nurses and microbiologists. Some hospitals have no on-site infectious diseases physician or full-time antimicrobial stewardship pharmacist, so the tool should distinguish advice that can be delivered locally from decisions requiring escalation. Queensland-wide variation also means that regional or local antibiograms, formularies and referral arrangements must shape the recommendations. A single standard pathway should not assume a regional hospital and a remote service can operate identically.
A useful analogy is the glass bottle recycling journey: just as collection, sorting and processing depend on clear hand-offs, prescribing, laboratory reporting and review depend on a connected workflow. In digital terms, that means using stable patient identifiers and interoperable interfaces built on standards such as HL7 FHIR where systems allow, plus a fallback screen when integrations are incomplete. The analogy also warns against losing information at every transfer.
Connect the tool to clinical work
The strongest case is an embedded clinical decision support tool within the digital medical record, opened from medication ordering or a microbiology result. It should check allergies, interactions, duplicate therapy and renal dosing, then offer de-escalation prompts when culture results become available. An alert that merely says no creates friction; a recommendation that explains why a narrower-spectrum option may be suitable is easier to act on and review.
Workflow support matters as much as technical integration. Where medication charts or discharge summaries remain partly paper-based, clinicians still need a concise summary and a way to record the prescribing decision digitally. Public hospital formularies and procurement rules also determine which agents are stocked and how quickly they reach a rural site; a clinically preferable antibiotic is not useful if it cannot be supplied. The network’s rural palliative care collaboration offers a useful model for building cross-site workflows around shared responsibilities rather than assuming every hospital has the same capacity. Lessons about communication, escalation and community follow-up can transfer to antimicrobial review.
Measure safety, equity and usefulness
Evaluation should begin with a clinically realistic baseline across partner hospitals. De-identified records can reveal how often empirical therapy differs from local guidance, how quickly results are reviewed and whether allergy or dose checks occur. A staged pilot can then compare supported decisions with usual practice, while clinician feedback tests usability. Ethics approval, data sharing agreements, a privacy impact assessment and clear cybersecurity responsibilities should be settled before identifiable data flow.
Success needs both prescribing and safety measures: time to appropriate treatment, review or de-escalation, antibiotic days, allergy checks, adverse drug events and unplanned escalation. Antimicrobial resistance, C. difficile infection and mortality are important outcomes, but smaller rural sites may need longer follow-up and careful interpretation. Balancing measures must capture alert overrides, interruptions, pharmacy workload and delays. Decision support should accompany audit and feedback, peer discussion and education rather than be treated as a complete antimicrobial stewardship program by itself.
Equity checks should examine who receives prompts and who benefits. Co-design with Aboriginal and Torres Strait Islander health services and communities can support appropriate language, communication and pathways that respect cultural safety and patient choice. Results should be stratified where numbers permit, and limitations reported openly. Digital access, health literacy and access to local follow-up must shape the pathway, not be left to routine processes.
Recommendations for a staged rollout
A credible rollout needs governance before code and funding beyond the pilot. A shared clinical group should set scope, approve rules, review incidents and monitor performance, with rural clinicians, consumers and Aboriginal and Torres Strait Islander representatives holding meaningful decision-making roles. Universities and health services can contribute data, evaluation capacity and implementation support, while keeping decisions accountable to the communities served.
The following measures provide a practical starting point for implementation:
- Set a narrow first scope, such as adult empiric therapy for sepsis and review after microbiology results, with clear rules for exclusions and specialist escalation.
- Co-design with rural prescribers, locums, nurses, pharmacists, microbiologists, consumers and Aboriginal and Torres Strait Islander health representatives, then test realistic clinical scenarios.
- Make recommendations explainable and reversible, showing the evidence source, patient data used, review time and a simple route for clinicians to accept, modify or decline.
- Pilot across several hospitals with common outcome measures, balancing prescribing gains against alert burden, pharmacy workload, safety events and unintended effects on access.
- Fund ongoing maintenance, training, governance and evaluation, including time for rural staff and community representatives to contribute beyond the initial pilot.
Convene the first co-design workshop with a rural hospital clinician, a stewardship pharmacist, a microbiologist, a digital health lead and a consumer representative. Define one shared use case, nominate pilot sites and agree on measures for safe, equitable prescribing. The immediate action is to publish the evaluation plan before clinical use begins, giving the Brisbane Diamantina Health Partners network a practical foundation for collaboration across Queensland’s rural and regional services.